Edition:
United Kingdom

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

22.50USD
21 Jun 2018
Change (% chg)

$1.33 (+6.28%)
Prev Close
$21.17
Open
$23.00
Day's High
$23.55
Day's Low
$21.26
Volume
518,850
Avg. Vol
159,640
52-wk High
$31.91
52-wk Low
$8.10

Chart for

About

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophi... (more)

Overall

Beta: --
Market Cap(Mil.): $557.18
Shares Outstanding(Mil.): 26.90
Dividend: --
Yield (%): --

Financials

  VYGR.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -2.30 -- --
ROI: -35.17 2.00 14.38
ROE: -45.36 3.49 16.08

BRIEF-Voyager Therapeutics Rpeorts Q1 GAAP Loss Per Share Of $0.63

* VOYAGER THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

10 May 2018

BRIEF-Voyager Therapeutics Reports Q4 GAAP Loss Per Share $0.40

* VOYAGER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

14 Mar 2018

BRIEF-Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease

* VOYAGER THERAPEUTICS ANNOUNCES LONGER-TERM DATA FROM ONGOING PHASE 1B TRIAL OF VY-AADC FOR ADVANCED PARKINSON’S DISEASE

09 Mar 2018

BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration

* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMER’S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES

20 Feb 2018

BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC

* VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE

23 Jan 2018

BRIEF-Ophthotech Announces Election Of Jane Pritchett Henderson, CFO And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

* OPHTHOTECH ANNOUNCES ELECTION OF JANE PRITCHETT HENDERSON, CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT AT VOYAGER THERAPEUTICS, TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

16 Jan 2018

BRIEF-BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics

* BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING‍​ Source text: (http://bit.ly/2CZEeZD) Further company coverage:

10 Jan 2018

Earnings vs. Estimates